Product image of Juvinelle (Dienogest, Estradiol Valerate) supplied by GNH India

Juvinelle

Active Ingredient:
Dienogest, Estradiol Valerate
Origin:
EU

Juvinelle (Dienogest, Estradiol Valerate)

Dienogest/Estradiol valerate, the active ingredients in Juvinelle, are a combined estrogen‑progestogen oral contraceptive presented as tablets for oral use. They work by suppressing ovulation and stabilising the endometrium, thereby preventing pregnancy and helping to regulate the menstrual cycle in women of reproductive age.

GNH India supplies Juvinelle as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this hormonal contraceptive. The company adheres to stringent quality standards and offers regulatory support for global distribution.

Manufacturer / TM Owner

Dr. Kade Pharmazeutische Fabrik Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Juvinelle, a combined estrogen‑progestogen oral contraceptive, is used in hormonal management of reproductive health.

  • Prevention of pregnancy: provides reliable contraception by inhibiting ovulation.
  • Regulation of menstrual cycle: helps achieve more predictable bleeding patterns.
  • Endometriosis symptom control: reduces pelvic pain associated with endometriosis.

How It Works

  • Juvinelle combines estradiol valerate, an estrogen that binds to estrogen receptors and stabilises the endometrial lining, with dienogest, a progestogen that binds to progesterone receptors. The estrogen component provides negative feedback to the hypothalamic‑pituitary axis, while the progestogen suppresses the luteinising hormone surge, together preventing follicular development and ovulation. Additionally, the progestogen thickens cervical mucus and alters endometrial growth, contributing to contraceptive efficacy.

Side Effects

Like all hormonal contraceptives, Juvinelle may be associated with a range of adverse reactions.

Common Side Effects

  • Nausea: mild stomach upset, especially during the first cycles.
  • Headache: tension‑type or migraine‑like headaches.
  • Breast tenderness: temporary swelling or discomfort.
  • Breakthrough bleeding: spotting between periods.

Serious or Rare Side Effects

  • Venous thromboembolism: deep vein thrombosis or pulmonary embolism.
  • Hypertensive crisis: sudden high blood pressure episodes.
  • Liver dysfunction: jaundice or abnormal liver enzymes.

Precautions & Warnings

Before prescribing Juvinelle, clinicians should consider several safety precautions to minimise risk.

  • Contraindication: avoid use in women who are pregnant or breastfeeding.
  • Smoking: do not prescribe to smokers over 35 years of age due to increased cardiovascular risk.
  • Cardiovascular disease: assess history of thromboembolic disorders, hypertension, or coronary artery disease.
  • Liver disease: use with caution in patients with active liver disease or hepatic tumors.
  • Medication review: evaluate concomitant use of drugs that affect coagulation or hormone metabolism.
  • Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture and light.

Avoid Interactions

Juvinelle can interact with other medicines, altering its effectiveness or increasing adverse effects.

Major Interactions (Avoid)

  • Combined hormonal contraceptives with enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce contraceptive efficacy.
  • Rifampicin or other potent CYP3A4 inducers: can markedly decrease hormone levels.
  • Anticoagulants (warfarin): may increase risk of thrombosis when combined with estrogen.

Moderate Interactions (Monitor Closely)

  • Antifungal agents (ketoconazole, itraconazole): may increase hormone concentrations.
  • St. John’s wort: may lower contraceptive effectiveness.
  • Selective serotonin reuptake inhibitors (SSRIs): may exacerbate mood changes or bleeding patterns.

Frequently Asked Questions

Juvinelle is a combined estrogen‑progestogen oral contraceptive indicated for the prevention of pregnancy and for regulation of the menstrual cycle in women of reproductive age. It may also be prescribed to manage symptoms associated with endometriosis.

The estradiol valerate component binds to estrogen receptors, stabilising the endometrial lining, while dienogest binds to progesterone receptors, suppressing the luteinising hormone surge and inhibiting ovulation. Together they also thicken cervical mucus and alter endometrial development, providing effective contraception.

The specific dosing regimen for Juvinelle is determined by the prescribing healthcare professional based on the product’s labeling and the patient’s individual needs. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

Juvinelle is classified as pregnancy category X, meaning it must not be used during pregnancy because it can cause fetal harm. It is also not recommended while breastfeeding, as hormonal exposure may affect milk production and infant health.

To order Juvinelle, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Juvinelle contains the specific progestogen dienogest together with estradiol valerate, offering a balance of estrogen and progestogen that may provide improved cycle control and reduced androgenic side effects compared with some older formulations that use levonorgestrel or norethisterone.

Store Juvinelle tablets at ambient temperature, preferably below 25 °C, in the original blister pack to protect from moisture and light. Keep the container tightly closed and out of reach of children.

Juvinelle is taken orally, typically once daily at the same time each day, as directed by the prescriber. The usual regimen follows a cyclic schedule of active tablets followed by a hormone‑free interval, but patients must follow the specific instructions provided with the product.

The most serious risks include venous thromboembolism (deep‑vein thrombosis or pulmonary embolism), arterial thrombosis leading to heart attack or stroke, and severe hypertension. Women with a history of clotting disorders, cardiovascular disease, or smoking over age 35 are at higher risk.

Juvinelle should not be used by women who are pregnant, breastfeeding, have known hypersensitivity to dienogest or estradiol valerate, have a history of thromboembolic disease, uncontrolled hypertension, active liver disease, or certain hormone‑sensitive cancers.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Dienogest, Estradiol Valerate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT